Thursday, June 25, 2026
🇺🇸 FDA

Pharmacovigilance · ICH E2A · SAE Triage

Seriousness Checker for ICH E2A SAE Criteria

Free ICH E2A seriousness criteria checker for pharmacovigilance professionals. Triage SAE status, distinguish seriousness from severity, and capture reporting context for clinical trial and post-marketing ICSR workflows.

Quick Answer

Under ICH E2A, an adverse event is a serious adverse event (SAE) if it results in death, is life-threatening, requires inpatient hospitalization or prolongs hospitalization, causes persistent or significant disability or incapacity, involves a congenital anomaly or birth defect, or is an important medical event that may jeopardize the patient or require intervention to prevent a serious outcome. This ICH E2A seriousness criteria checker supports pharmacovigilance ICSR triage and case processing. Seriousness is a regulatory outcome classification—distinct from clinical severity grading—and does not by itself establish causality, expectedness, or expedited reportability.

ICH E2A seriousness criteria (any one = SAE)

Death · Life-threatening · Hospitalization/prolongation · Disability/incapacity · Congenital anomaly · Important medical event

Seriousness is outcome-based regulatory classification—not clinical severity grade, causality, or expectedness.

Interactive checklist

Does the event meet an ICH E2A seriousness criterion?

Select all criteria that apply. Under ICH E2A, one selected criterion is enough for the adverse event to be treated as serious for safety evaluation and case processing.

ICH E2A seriousness criteria

If none apply, leave the checklist empty and generate a non-serious assessment.

Assessment result

Result pending

Select criteria and run the checker.

Selected criteria

  • No criteria selected yet.

Reporting note

Run the checker to generate a reporting note.

How to Use This Checker

1
Review the case narrative, discharge summary, or investigator report for patient outcome—not just event intensity or MedDRA term severity.
2
Select every ICH E2A seriousness criterion supported by documented facts: death, life-threatening, hospitalization, disability, congenital anomaly, or important medical event.
3
Run the checker. One selected criterion classifies the event as serious for SAE handling; no selection indicates non-serious by selected criteria (subject to new information).
4
Document the seriousness rationale in the safety database and proceed to causality, expectedness, and expedited reporting assessment per protocol or post-marketing SOP.

ICH E2A Seriousness Criteria

ICH E2A defines a serious adverse event or reaction by outcome and patient risk. The seriousness criteria are death, life-threatening event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, and other medically important events.

The assessment is not a causality decision. A case can be serious even when the relationship to the investigational medicinal product or marketed product is still unknown, pending, or later assessed as unrelated.

Seriousness vs Severity

Seriousness

A regulatory classification based on outcomes or threat to the patient. It answers: does the event meet an SAE reporting criterion?

Severity

A clinical intensity grade such as mild, moderate, severe, Grade 1-5, or CTCAE grade. It answers: how intense was the event?

A severe event is not automatically serious. For example, severe nausea may be non-serious if it does not meet an SAE criterion. Conversely, a clinically modest event can be serious if it requires intervention to prevent hospitalization, disability, or death.

Important Medical Event Examples

ICH E2A allows medical and scientific judgment for events that may jeopardize the patient or require intervention to prevent a serious outcome. Depending on the product, indication, patient risk, and intervention required, examples may include:

  • Allergic bronchospasm requiring intensive treatment in an emergency room or at home.
  • Blood dyscrasias or convulsions that do not result in hospitalization.
  • Development of drug dependency or drug abuse.
  • Medically significant overdose, medication error, or exposure scenario requiring urgent intervention.
  • Events requiring medical or surgical intervention to prevent hospitalization, disability, or death.

SAE vs AE in Safety Workflows

Concept Meaning PV implication
AE Any untoward medical occurrence in a patient or clinical investigation subject administered a medicinal product. Captured and assessed according to protocol, label, local law, and company SOPs.
SAE An adverse event meeting one or more ICH E2A seriousness outcomes. Triggers urgent review, case processing, causality assessment, expectedness review, and possible expedited reporting.
SUSAR A suspected unexpected serious adverse reaction in a clinical trial context. Requires seriousness plus suspected causality plus unexpectedness under applicable trial reporting rules.

ICSR Workflow for Pharma Professionals

Seriousness assessment is an early step in individual case safety report (ICSR) processing under ICH E2A and post-marketing definitions in ICH E2D. When a case arrives from a clinical site, patient, HCP, or spontaneous report, safety teams confirm minimum validity, code the event in MedDRA, apply ICH E2A seriousness criteria, then assess causality and expectedness before determining reportability and regulatory clock start.

A typical workflow: (1) intake and duplicate check in the safety database; (2) seriousness triage with this checker; (3) WHO-UMC or company causality assessment; (4) expectedness against IB, SmPC, or label for trial or marketed products; (5) SUSAR determination for investigational studies; (6) EudraVigilance, FDA FAERS, or regional authority submission within 7-day or 15-day timelines where applicable.

Use our SUSAR Assessment tool after confirming SAE status, Causality Assessment for WHO-UMC categories, ICSR Case Processing for validity and follow-up fields, and Signal Detection when aggregate disproportionality screening follows case-level review.

Clinical Trial and Post-Marketing Context

Clinical trials

Seriousness is usually assessed immediately after awareness. Sponsors then evaluate causality, expectedness, protocol reporting requirements, and whether the case is a SUSAR or other expedited safety report.

Post-marketing

Serious cases are processed as ICSRs under applicable regional rules. ICH E2D supports post-approval safety definitions and emphasizes medically confirmed, valid, and reportable case handling.

Evidence & Sources

Frequently Asked Questions

Under ICH E2A, an adverse event is serious if it results in death, is life-threatening, requires inpatient hospitalization or prolongs hospitalization, results in persistent or significant disability or incapacity, causes a congenital anomaly or birth defect, or is another important medical event that may jeopardize the patient or require intervention to prevent one of those outcomes. One criterion is sufficient for SAE classification.
No. Seriousness is a regulatory reporting concept based on patient outcome or threat under ICH E2A. Severity describes clinical intensity—mild, moderate, severe, CTCAE grade, or similar scales. A severe headache may be non-serious if no seriousness criterion is met. A clinically modest event can be serious if it requires intervention to prevent hospitalization, disability, or death.
An important medical event (IME) is an event that may not immediately result in death, hospitalization, disability, or congenital anomaly but may jeopardize the patient or require medical or surgical intervention to prevent one of those outcomes. ICH E2A allows medical and scientific judgment. Examples include allergic bronchospasm requiring emergency treatment, blood dyscrasias, convulsions, drug dependency or abuse, and overdose requiring urgent intervention.
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a medicinal product, whether or not considered related to the product. A serious adverse event (SAE) is an AE meeting one or more ICH E2A seriousness criteria. Seriousness does not establish causality, expectedness, or whether the case is a SUSAR or expedited ICSR.
Not always. In clinical trials, expedited reporting often depends on seriousness plus suspected causal relationship plus unexpectedness—for example SUSAR assessment under ICH E2A and E2D. In post-marketing pharmacovigilance, serious valid ICSRs are generally reportable, but timelines and follow-up depend on region, case validity, and whether the reaction is expected in the reference safety information.
Emergency room or urgent care treatment alone does not automatically meet the hospitalization seriousness criterion under ICH E2A, which requires inpatient admission or prolongation of an existing inpatient stay. However, ER treatment with intervention to prevent death, disability, or hospitalization may qualify as an important medical event. Document the clinical narrative and intervention clearly in the ICSR.
Death means the adverse event resulted in the patient or subject dying. Life-threatening means the person was at immediate risk of death at the time of the event—not merely that a more severe form might have been fatal. Fatal or life-threatening SUSARs in clinical trials commonly trigger shorter expedited reporting clocks (often 7 calendar days) compared with other serious unexpected reactions (often 15 days), per applicable trial rules.
Under ICH E2A, an adverse event is serious when it involves a congenital anomaly or birth defect associated with exposure to a medicinal product— including paternal or in utero exposure contexts documented in the case. This criterion applies regardless of whether hospitalization or disability occurred. Congenital findings require careful MedDRA coding and follow-up in pregnancy and reproductive safety workflows.
Persistent or significant disability or incapacity means a substantial disruption of the person's ability to conduct normal life functions. Temporary inability to work during acute illness may not qualify unless the disruption is significant and persistent per medical judgment. Examples can include permanent sensory loss, mobility impairment, or cognitive incapacity that materially affects daily function.
Medically important events include outcomes that jeopardize the patient or require intervention to prevent serious outcomes without inpatient admission. ICH E2A examples include allergic bronchospasm treated in the ER or at home, blood dyscrasias, convulsions, drug dependency or abuse, and significant overdose. The IME criterion captures clinically important events that regulators expect in safety databases even when other seriousness criteria are absent.
Seriousness is the first gate in SUSAR triage. A SUSAR is a suspected unexpected serious adverse reaction—requiring seriousness, a reasonable suspected causal relationship, and unexpectedness against the reference safety information. After confirming SAE status with this checker, continue to the SUSAR Assessment tool (/pharmacovigilance/susar-assessment) to evaluate causality, expectedness, minimum case criteria, and the likely 7-day or 15-day expedited reporting timeline.
Under EU pharmacovigilance practice, marketing authorization holders generally submit valid serious ICSRs to EudraVigilance within 15 calendar days of becoming aware of the case. Fatal or life-threatening unexpected reactions in clinical trials may require reporting within 7 calendar days with follow-up within 8 additional days. The 15-day clock applies to post-authorization serious reports meeting validity criteria—not to every AE or non-serious case.

Related Pharmacovigilance Tools

SUSAR SUSAR Assessment WHO Causality Assessment PRR Signal Detection ICSR Case Processing PT MedDRA Lookup

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.